MedJ takes you straight to ASCO 2025.
Professor Nicolas Girard from Institut Curie in Paris, France, rewrote the history of thymic carcinoma treatment with the world's first EORTC-ETOP NIVOTHYM Phase III study, overcoming the challenge of immunotherapy resistance!